已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

医学 索拉非尼 肝细胞癌 内科学 临床终点 危险系数 不利影响 肿瘤科 随机对照试验 肝功能 无进展生存期 放射治疗 置信区间 化疗
作者
Laura A. Dawson,Kathryn A Winter,Jennifer Jane Knox,Andrew X. Zhu,Sunil Krishnan,Chandan Guha,Lisa Ann Kachnic,Michael T. Gillin,Theodore Sunki Hong,Tim Craig,Terence Marques Williams,Ali Hosni,Eric Xueyu Chen,Anne M. Noonan,Eugene Jon Koay,Rishi Sinha,Michael I. Lock,Nitin Ohri,Jennifer Anne Dorth,Guila Delouya
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:11 (2): 136-136 被引量:119
标识
DOI:10.1001/jamaoncol.2024.5403
摘要

Importance: Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy. Objective: To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone. Design, Setting, and Participants: This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metastases, and macrovascular invasion. Eligible patients had HCC unsuitable for or refractory to standard local-regional therapies and were candidates for first-line systemic therapy. Data were collected from April 2013 to March 2021, and data were analyzed from July 2022 to August 2023. Intervention: Personalized SBRT, 27.5 to 50 Gy in 5 fractions. Main Outcomes and Measures: The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS), adverse events, and quality of life. Results: Of 193 patients randomized, 177 were eligible. Accrual was stopped early due to a change in standard-of-care systemic therapy. Of 177 included patients, 150 (84.7%) were male, and the median (IQR) age was 66 (60-72) years. Macrovascular invasion was seen in 131 (74.0%). As of July 1, 2022, the median OS was 12.3 months (90% CI, 10.6-14.3) with sorafenib vs 15.8 months (90% CI, 11.4-19.2) following SBRT and sorafenib (hazard ratio [HR], 0.77; 90% CI, 0.59-1.01; 1-sided P = .06). Adjusting for stratification factors, OS was improved with SBRT (HR, 0.72; 95% CI, 0.52-0.99; 2-sided P = .04). Median PFS was improved from 5.5 months (95% CI, 3.4-6.3) with sorafenib to 9.2 months (95% CI, 7.5-11.9) with SBRT and sorafenib (HR, 0.55; 95% CI, 0.40-0.75; 2-sided P < .001). Treatment-related grade 3 or higher adverse events were seen in 37 of 88 (42%) and 39 of 83 (47%) of patients treated with sorafenib vs SBRT and sorafenib, respectively (P = .52). There were 2 treatment-related deaths in the sorafenib group (death not otherwise specified and liver failure) and 1 in the SBRT and sorafenib group (lung infection). At 6 months, improved quality of life was seen in 2 of 20 (10%) and 6 of 17 (35%) of patients treated with sorafenib and SBRT and sorafenib, respectively. Conclusions and Relevance: In this phase 3 randomized clinical trial, among patients with locally advanced HCC, SBRT was associated with a clinically important but not statistically significant improved overall survival compared with sorafenib alone. Trial Registration: ClinicalTrials.gov Identifier: NCT01730937.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘻嘻完成签到,获得积分10
2秒前
没名字完成签到 ,获得积分10
4秒前
去内蒙的小企鹅完成签到 ,获得积分10
4秒前
5秒前
文文武完成签到 ,获得积分10
5秒前
6秒前
zz完成签到,获得积分10
7秒前
藕饼完成签到 ,获得积分10
8秒前
李健的粉丝团团长的应助被DW采纳,获得10
8秒前
吉祥高趙完成签到 ,获得积分10
8秒前
8秒前
芒果在散步完成签到 ,获得积分10
9秒前
科研通AI65的应助被俏皮以旋采纳,获得30
9秒前
10秒前
Cakoibao的应助被洋芋二号采纳,获得10
10秒前
spr完成签到 ,获得积分10
11秒前
小丸子完成签到,获得积分20
11秒前
司徒宝发布了新的文献求助10
12秒前
开朗的千雁完成签到 ,获得积分10
13秒前
GIMI完成签到,获得积分10
13秒前
601完成签到 ,获得积分10
13秒前
筝zheng完成签到 ,获得积分10
16秒前
孙崇发布了新的文献求助10
18秒前
19秒前
大模型的应助被DW采纳,获得10
20秒前
云在青天水在瓶完成签到,获得积分10
21秒前
22秒前
共享精神的应助被zz采纳,获得10
23秒前
陈老完成签到 ,获得积分10
23秒前
学霸业的应助被英勇羿采纳,获得10
23秒前
云淡风轻完成签到,获得积分10
24秒前
FF发布了新的文献求助200
24秒前
25秒前
Lsw完成签到 ,获得积分10
25秒前
77小姐完成签到 ,获得积分10
27秒前
英勇羿完成签到,获得积分10
28秒前
冯小晴完成签到 ,获得积分10
28秒前
29秒前
30秒前
今后的应助被科研通管家采纳,获得10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184828
求助须知:如何正确求助?哪些是违规求助? 9573791
关于积分的说明 21833034
捐赠科研通 7782127
什么是DOI,文献DOI怎么找? 3434405
关于科研通互助平台的介绍 2558545
邀请新用户注册赠送积分活动 2481067